American vaccine manufacturer Novavax has announced plans to share its vaccine technology with the Bill & Melinda Gates Medical Research Institute. Novavax has signed a three-year deal to share its vaccine adjuvant, Matrix-M, with the nonprofit biotech, which aims to develop vaccines for major health threats such as malaria, tuberculosis, and Shigella. Adjuvants are crucial components of vaccines that boost the immune system, making the shot more powerful and durable. Gates MRI is committed to developing biomedical interventions that address global health concerns for those in the greatest need and focuses on tackling TB, malaria, diarrheal diseases, and maternal, newborn, and child illnesses in low and middle-income countries. It also lists Shigella vaccines in its pipeline of pre-clinical work, which could be a possible target for the Novavax adjuvant.
Denial of responsibility! TechCodex is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessory action within 24 hours.
Jessica Irvine is a tech enthusiast specializing in gadgets. From smart home devices to cutting-edge electronics, Jessica explores the world of consumer tech, offering readers comprehensive reviews, hands-on experiences, and expert insights into the coolest and most innovative gadgets on the market.
